• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Solitary Neurofibroma

Article

This new-onset “growth” was removed and shown to be a solitary neurofibroma, which is not an indication of any of the genodermatoses marked by a multiplicity of such neoplasms.

A 47-year-old man sought medical attention because of a new-onset “growth” on the right arm. He was in good health and had no significant past medical history.

Key point: This uniform-appearing, flesh-colored, soft papule is almost certainly benign. A shave biopsy with light electrodesiccation to the base would likely serve both diagnostic and therapeutic purposes.

Treatment: The lesion was removed as noted above, and proved to be a solitary neurofibroma.  

Note: A single neurofibroma is not an indication of any of the various genodermatoses that are characterized by a multiplicity of such neoplasms. No workup was entertained, and the removal site healed nicely.

Related Content
Atopic Dermatitis First, Now Onto Asthma for Enveda's Oral Small Molecule Anti-inflammatory Candidate

Atopic Dermatitis First, Now Onto Asthma for Enveda's Oral Small Molecule Anti-inflammatory Candidate

Grace Halsey
February 7th 2025
Article

The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.

Dupilumab Drug Survival Rates Superior to Those for Upadacitinib and Tralokinumab in Atopic Dermatitis: Large-Scale, Real-World Data

Dupilumab Drug Survival Rates Superior to Those for Upadacitinib and Tralokinumab in Atopic Dermatitis: Large-Scale, Real-World Data

Grace Halsey
February 7th 2025
Article

A first large-scale comparison of length of treatment with advanced AD therapies also identified reasons for discontinuation and examined prior use of biologics and JAK inhibitors.

Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use / image Eric Simpson, MD, MRC, Oregon Health & Science University

Atopic Dermatitis Update: Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use

Grace Halsey
February 5th 2025
Article

Improvement in

Study Identifies Key Symptoms of Topical Steroid Withdrawal: Daily Dose / image credit: ©New Africa/AdobeStock

Study Identifies Key Symptoms of Topical Steroid Withdrawal: Daily Dose

Sydney Jennings
February 5th 2025
Article

Your daily dose of the clinical news you may have missed.

Delgocitinib Effective in Adolescents with CHE in Phase 3 DELTA TEEN Trial / image credit Sonja Molin, MD Queen’s University

Delgocitinib Effective in Adolescents with CHE in Phase 3 DELTA TEEN Trial

Grace Halsey
February 4th 2025
Article

With no FDA-approved treatments for moderate-to-severe chronic hand eczema in the teen population, the late-stage topline data are very promising.

Tapinarof 1% Cream Significantly Improves Patient Reported Outcomes, Including Family QoL, in Atopic Dermatitis / image credit courtesy of OHSU

Tapinarof 1% Cream Significantly Improves Patient Reported Outcomes, Including Family QoL, in Atopic Dermatitis

Grace Halsey
January 27th 2025
Article

Tapinarof 1% cream when used as topical monotherapy led to statistically significant and sustained improvements in QoL, sleep, and other PROs across age groups.

© 2025 MJH Life Sciences

All rights reserved.